Skip to Main Content
Table 2

Final proportional hazards modela for breast cancer specific survival at 10 years follow-up

VariableUnivariateMultivariate
RRb (95% CI)PRR (95% CI)P
A. All patients (n = 241)     
Tumor size     
 <2 cm 1.00  1.00  
 ≥2 cm 3.09 (1.75–5.46) 0.0001 2.08 (1.14–3.80) 0.02 
Lymph nodes     
 Negative 1.00  1.00  
 Positive 2.78 (1.60–4.83) 0.0003 2.58 (1.45–4.56) 0.001 
p53     
 Negative 1.00  1.00  
 Positive 2.57 (1.54–4.28) 0.0003 1.70 (0.99–2.90) 0.05 
p27Kip1     
 Negative 1.00  1.00  
 Positive 0.43 (0.23–0.78) 0.006 0.51 (0.28–0.95) 0.03 
Cyclin E     
 Negative 1.00  1.00  
 Positive 2.63 (1.58–4.38) 0.0002 1.99 (1.16–3.41) 0.01 
GMP     
 None 1.00  1.00  
 >0 2.68 (1.55–4.62) 0.0004 2.34 (1.31–4.21) 0.004 
B. Node-negative disease (n = 120)     
Tumor size     
 <2 cm 1.00  1.00  
 ≥2 cm 1.68 (0.68–4.13) 0.26 0.99 (0.39–2.55) 0.99 
p53     
 Negative 1.00  1.00  
 Positive 2.48 (0.98–6.30) 0.06 1.20 (0.44–3.24) 0.73 
p27Kip1     
 Negative 1.00  1.00  
 Positive 0.21 (0.06–0.72) 0.01 0.24 (0.07–0.85) 0.03 
Cyclin E     
 Negative 1.00  1.00  
 Positive 5.13 (2.01–13.0) 0.0006 3.53 (1.34–9.28) 0.01 
GMP     
 None 1.00  1.00  
 >0 1.85 (0.67–5.14) 0.24 1.78 (0.60–5.25) 0.30 
C. Node-positive disease (n = 100)     
Tumor size     
 <2 cm 1.00  1.00  
 ≥2 cm 3.45 (1.43–8.32) 0.006 3.95 (1.47–10.6) 0.007 
p53     
 Negative 1.00  1.00  
 Positive 2.20 (1.15–4.22) 0.02 1.99 (0.99–4.00) 0.05 
p27Kip1     
 Negative 1.00  1.00  
 Positive 0.74 (0.36–1.52) 0.41 0.87 (0.41–1.83) 0.70 
Cyclin E     
 Negative 1.00  1.00  
 Positive 2.03 (1.02–4.03) 0.04 1.24 (0.59–2.61) 0.58 
GMP     
 None 1.00  1.00  
 >0 3.16 (1.56–6.44) 0.002 3.16 (1.44–6.95) 0.004 
VariableUnivariateMultivariate
RRb (95% CI)PRR (95% CI)P
A. All patients (n = 241)     
Tumor size     
 <2 cm 1.00  1.00  
 ≥2 cm 3.09 (1.75–5.46) 0.0001 2.08 (1.14–3.80) 0.02 
Lymph nodes     
 Negative 1.00  1.00  
 Positive 2.78 (1.60–4.83) 0.0003 2.58 (1.45–4.56) 0.001 
p53     
 Negative 1.00  1.00  
 Positive 2.57 (1.54–4.28) 0.0003 1.70 (0.99–2.90) 0.05 
p27Kip1     
 Negative 1.00  1.00  
 Positive 0.43 (0.23–0.78) 0.006 0.51 (0.28–0.95) 0.03 
Cyclin E     
 Negative 1.00  1.00  
 Positive 2.63 (1.58–4.38) 0.0002 1.99 (1.16–3.41) 0.01 
GMP     
 None 1.00  1.00  
 >0 2.68 (1.55–4.62) 0.0004 2.34 (1.31–4.21) 0.004 
B. Node-negative disease (n = 120)     
Tumor size     
 <2 cm 1.00  1.00  
 ≥2 cm 1.68 (0.68–4.13) 0.26 0.99 (0.39–2.55) 0.99 
p53     
 Negative 1.00  1.00  
 Positive 2.48 (0.98–6.30) 0.06 1.20 (0.44–3.24) 0.73 
p27Kip1     
 Negative 1.00  1.00  
 Positive 0.21 (0.06–0.72) 0.01 0.24 (0.07–0.85) 0.03 
Cyclin E     
 Negative 1.00  1.00  
 Positive 5.13 (2.01–13.0) 0.0006 3.53 (1.34–9.28) 0.01 
GMP     
 None 1.00  1.00  
 >0 1.85 (0.67–5.14) 0.24 1.78 (0.60–5.25) 0.30 
C. Node-positive disease (n = 100)     
Tumor size     
 <2 cm 1.00  1.00  
 ≥2 cm 3.45 (1.43–8.32) 0.006 3.95 (1.47–10.6) 0.007 
p53     
 Negative 1.00  1.00  
 Positive 2.20 (1.15–4.22) 0.02 1.99 (0.99–4.00) 0.05 
p27Kip1     
 Negative 1.00  1.00  
 Positive 0.74 (0.36–1.52) 0.41 0.87 (0.41–1.83) 0.70 
Cyclin E     
 Negative 1.00  1.00  
 Positive 2.03 (1.02–4.03) 0.04 1.24 (0.59–2.61) 0.58 
GMP     
 None 1.00  1.00  
 >0 3.16 (1.56–6.44) 0.002 3.16 (1.44–6.95) 0.004 
a

Adjusted for all missing variables. Final model excludes cases for which adjustment was not possible (n = 6); cases with unknown nodal status are not included.

b

RR, relative risk; CI, confidence interval; GMP, glomeruloid microvascular proliferation.

Close Modal

or Create an Account

Close Modal
Close Modal